Toll-Like Receptor Homolog CD180 Expression Is Diminished on Natural Autoantibody-Producing B Cells of Patients with Autoimmune CNS Disorders

Table 1

Clinical characteristics of neuromyelitis optica spectrum disorder (NMOSD) patients, relapsing-remitting multiple sclerosis (RRMS) patients, and healthy controls (HC) involved in the study.

	HC	NMOSD	RRMS
Gender (female), (%)	4 (66.7%)	7 (58.3%)	13 (86.7%)
Anti-AQP4 antibody positivity, (%)	—	8 (66.7%)	—
Median age, (range)	47.5 (25-52)	50.5 (30-71)	42 (22-65)
Median age at onset, (range)	—	44 (16-69)	28 (12-42)
Median disease duration, (range)	—	8 (0.5-22)	15 (1-34)
No. of relapse,	—
EDSS, median (range)	—	2 (0-6.5)	1.5 (0-8)
DMT drug	—	—	10 (66.7%)
Immunosuppressive drug	—	12 (100%)	1 (6.7%)^♦

DMT drugs in MS included dimethyl fumarate (4), interferon β1a (2), fingolimod (2), glatiramer acetate (1), and alemtuzumab (1). HC = healthy controls; NMOSD = neuromyelitis optica spectrum disorder; MS = multiple sclerosis; AQP4 = aquaporin-4; EDSS = Expanded Disability Status Scale; DMT = disease-modifying therapies. ^♦One RRMS patient received immunosuppressive therapy due to the first attack of the disease; first, high-dose parenteral steroid therapy was applied, followed by oral steroid treatment, which was ceased due to visual improvement of the patient.